Metsera, Inc. (MTSR) Research

Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.

Market snapshot

Symbol
MTSR
Price
$70.50
Day change
-0.35%
Market cap
$7.4B
P/E ratio
-23.55x
52-week range
12.3-83.8599
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$55.50

Peer companies

  • Abivax S.A. (ABVX)
  • Arcellx, Inc. (ACLX)
  • Arrowhead Pharmaceuticals, Inc. (ARWR)
  • Axsome Therapeutics, Inc. (AXSM)
  • CRISPR Therapeutics AG (CRSP)
  • Cytokinetics, Incorporated (CYTK)
  • Merus N.V. (MRUS)
  • Nuvalent, Inc. (NUVL)

Recent insider activity

  • FMR LLC — J-Other (2230450 shares) on 2025-11-13
  • ARCH Venture Partners XII, LLC — D-Return (8313680 shares) on 2025-11-13
  • Marso Steven — A-Award (17000 shares) on 2025-11-13
  • Marso Steven — D-Return (120000 shares) on 2025-11-13
  • Marso Steven — D-Return (21279 shares) on 2025-11-13

Open Metsera, Inc. (MTSR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.